| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00808132 | Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis | PHASE3 | COMPLETED | 1,886 | — | — | Jan 1, 2009 | Feb 1, 2011 | Apr 8, 2014 | 178 | United States, Argentina +10 |
| NCT00396799 | Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women | PHASE1 | COMPLETED | - | — | — | Nov 1, 2006 | Nov 1, 2006 | Mar 13, 2007 | - | — |
Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. If both the pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted. Results were summarized for two definitions of hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia); definition 1: participants were considered to have a diagnosis of hyperplasia when the 3 pathologists disagreed but at least 1 pathologist determined hyperplasia; definition 2: participants were considered to have a diagnosis of hyperplasia if at least 2 of the 3 pathologists agreed on the diagnosis.
BMD measurements of the anteroposterior lumbar spine were acquired by using dual-energy x-ray absorptiometry (DXA) scans, twice at Month 12 for a subset of participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. Mean percentage change from baseline of the 2 readings were reported.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | bazedoxifene 20 mg/conjugated estrogens 0.45 mg |
| 2 | EXPERIMENTAL | bazedoxifene 20 mg/conjugated estrogens 0.625 mg |
| 3 | EXPERIMENTAL | bazedoxifene 20 mg |
| 4 | ACTIVE_COMPARATOR | Prempro |
| 5 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| bazedoxifene 20 mg/ conjugated estrogens 0.45 mg | DRUG | One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year. |
| bazedoxifene 20 mg/ conjugated estrogens 0.625 mg | DRUG | One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year. |
| bazedoxifene 20 mg | DRUG | One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year. |
| conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg | DRUG | One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year. |
| Placebo | DRUG | One capsule, placebo (over-encapsulated), once a day for one year. |
| bazedoxifene/conjugated estrogens | DRUG | - |
Inclusion Criteria: * Generally healthy, postmenopausal women, aged 40 to 64 seeking treatment for menopausal symptoms * At least 12 months of spontaneous amenorrhea, OR 6 months spontaneous amenorrhea with follicle-stimulating hormone (FSH) levels \> 40 mIU/mL * Intact Uterus Exclusion Criteria: ...